Tarsus Pharmaceuticals, Inc.
TARS
Classificação em ações
#4682
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Preço da ação
$69.69
Valor de mercado
$3.26B
Variação (1 dia)
2.38%
Variação (1 ano)
-4.44%
País
US
Negociar Tarsus Pharmaceuticals, Inc. (TARS)
Categoria
Healthcare
EPS de Tarsus Pharmaceuticals, Inc. (TARS)
EPS em June 2026 TTM: $-1.09
De acordo com os últimos relatórios financeiros e o preço das ações da Tarsus Pharmaceuticals, Inc., o EPS atual da empresa (TTM) é $-1.09. No final de 2023, a empresa teve um EPS de $-4.62, um aumento em relação a ao EPS de 2022, que foi de $-2.52.
Histórico de EPS da Tarsus Pharmaceuticals, Inc. de 2018 até 2026
EPS no final de cada ano
| Ano | EPS | Alterar |
|---|---|---|
| 2026 (TTM) | $-1.09 | -64.50% |
| 2024 | $-3.07 | -33.55% |
| 2023 | $-4.62 | 83.33% |
| 2022 | $-2.52 | 276.12% |
| 2021 | $-0.67 | -49.24% |
| 2020 | $-1.32 | 450.00% |
| 2019 | $-0.24 | -22.58% |
| 2018 | $-0.31 | 0.00% |
EPS de empresas semelhantes ou concorrentes
| Empresa | EPS | Diferença de EPS | País |
|---|---|---|---|
| $17.32 | -1,688.99% |
US
|
|
| $-7.98 | 632.11% |
US
|
|
| $-5.29 | 385.32% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,644.95% |
NL
|
